Alexion, AstraZeneca's rare-disease group, maintains a major UK presence developing complement-based therapies for ultra-rare disorders.
Alexion, AstraZeneca's rare-disease group, maintains a major UK presence developing complement-based therapies for ultra-rare disorders.
Global Leadership
Advanced therapeutic development, sterile formulation, and quality assurance.
Global equity markets open August 2026 on a historic high as rumored $400B AstraZeneca-BMS merger talks and C…
Register to manage your profile, publish articles to our readers, list your product catalogue and post jobs — all from one dashboard.